Koshinski Asset Management Inc. Sells 182 Shares of AstraZeneca PLC $AZN

Koshinski Asset Management Inc. decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,571 shares of the company’s stock after selling 182 shares during the quarter. Koshinski Asset Management Inc.’s holdings in AstraZeneca were worth $459,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of AZN. Goldman Sachs Group Inc. increased its holdings in shares of AstraZeneca by 30.9% during the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after acquiring an additional 3,224,251 shares in the last quarter. Valeo Financial Advisors LLC increased its holdings in shares of AstraZeneca by 14,797.3% during the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock valued at $162,306,000 after acquiring an additional 2,307,047 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of AstraZeneca by 406.9% during the first quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after acquiring an additional 1,621,974 shares in the last quarter. Boston Partners increased its holdings in shares of AstraZeneca by 35.9% during the first quarter. Boston Partners now owns 5,036,645 shares of the company’s stock valued at $368,712,000 after acquiring an additional 1,329,166 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of AstraZeneca by 650.1% during the first quarter. Deutsche Bank AG now owns 1,234,847 shares of the company’s stock valued at $90,761,000 after acquiring an additional 1,070,223 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Finally, Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Stock Down 1.0%

Shares of NASDAQ:AZN opened at $83.87 on Tuesday. The company has a market capitalization of $260.11 billion, a PE ratio of 31.53, a price-to-earnings-growth ratio of 1.56 and a beta of 0.36. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The business has a fifty day moving average price of $80.42 and a two-hundred day moving average price of $73.97. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $86.57.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.24 EPS. Analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a $0.505 dividend. This represents a yield of 200.0%. The ex-dividend date was Friday, August 8th. AstraZeneca’s dividend payout ratio is 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.